{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:17:31Z","timestamp":1790252251472,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"publisher","award":["43\/16"],"award-info":[{"award-number":["43\/16"]}],"id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This pilot study aimed on generating insight on alterations in circulating immune cells during the use of FOLFIRINOX and gemcitabine\/nab-paclitaxel in pancreatic ductal adenocarcinoma (PDAC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>Peripheral blood mononuclear cells were isolated before and 30\u00a0days after initiation of chemotherapy from 20 patients with advanced PDAC. Regulatory T cells (FoxP3+) and immune checkpoints (PD-1 and TIM-3) were analyzed by flow cytometry and immunological changes were correlated with clinical outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Heterogeneous changes during chemotherapy were observed in circulating T-cell subpopulations with a pronounced effect on PD-1+ CD4+\/CD8+ T cells. An increase in FoxP3+ or PD-1+ T cells had no significant effect on survival. An increase in TIM3+\/CD8+ (but not TIM3+\/CD4+) T cells was associated with a significant inferior outcome: median progression-free survival in the subgroup with an increase of TIM-3+\/CD8+ T cells was 6.0 compared to 14.0\u00a0months in patients with a decrease\/no change (<jats:italic>p<\/jats:italic>\u2009=\u20090.026); corresponding median overall survival was 13.0 and 20.0\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.011), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Chemotherapy with FOLFIRNOX or gemcitabine\/nab-paclitaxel induces variable changes in circulating T-cell populations that may provide prognostic information in PDAC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-021-02620-x","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T19:06:05Z","timestamp":1618859165000},"page":"2394-2401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel"],"prefix":"10.1007","volume":"23","author":[{"given":"L.","family":"Sams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bararia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Haebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. B.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rataj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-2127","authenticated-orcid":false,"given":"S.","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"9","key":"2620_CR1","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/cam4.767","volume":"5","author":"AS Quante","year":"2016","unstructured":"Quante AS, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649\u201356.","journal-title":"Cancer Med"},{"issue":"18","key":"2620_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"19","key":"2620_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"2620_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788\u2013802.","journal-title":"Cancer Cell"},{"key":"2620_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3389\/fimmu.2019.01654","volume":"10","author":"JW Opzoomer","year":"2019","unstructured":"Opzoomer JW, et al. Cytotoxic chemotherapy as an immune stimulus: a molecular perspective on turning up the immunological heat on cancer. Front Immunol. 2019;10:1654.","journal-title":"Front Immunol"},{"issue":"1","key":"2620_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115\u201323.","journal-title":"Br J Cancer"},{"issue":"11","key":"2620_CR7","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","volume":"20","author":"SV Hato","year":"2014","unstructured":"Hato SV, et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2620_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt349","volume":"25","author":"AG Duffy","year":"2014","unstructured":"Duffy AG, Greten TF. Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol. 2014;25(1):24\u201332.","journal-title":"Ann Oncol"},{"key":"2620_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531\u201364.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2620_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3892\/ijo.2017.4032","volume":"51","author":"C Liu","year":"2017","unstructured":"Liu C, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Int J Oncol. 2017;51(2):686\u201394.","journal-title":"Int J Oncol"},{"issue":"12","key":"2620_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00262-017-2053-4","volume":"66","author":"F Bengsch","year":"2017","unstructured":"Bengsch F, et al. CTLA-4\/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother. 2017;66(12):1609\u201317.","journal-title":"Cancer Immunol Immunother"},{"issue":"27","key":"2620_CR12","doi-asserted-by":"publisher","first-page":"40992","DOI":"10.18632\/oncotarget.10038","volume":"7","author":"A Diana","year":"2016","unstructured":"Diana A, et al. Prognostic value, localization and correlation of PD-1\/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7(27):40992\u20131004.","journal-title":"Oncotarget"},{"issue":"4","key":"2620_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3892\/or.2015.4170","volume":"40","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Association between Tim3 and Gal9 expression and gastric cancer prognosis. Oncol Rep. 2018;40(4):2115\u201326.","journal-title":"Oncol Rep"},{"issue":"2","key":"2620_CR14","doi-asserted-by":"publisher","first-page":"e30676","DOI":"10.1371\/journal.pone.0030676","volume":"7","author":"X Gao","year":"2012","unstructured":"Gao X, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE. 2012;7(2):e30676.","journal-title":"PLoS ONE"},{"issue":"1","key":"2620_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cpt.1659","volume":"107","author":"SF Kruger","year":"2020","unstructured":"Kruger SF, et al. Challenges in clinical trial design for T cell-based cancer immunotherapy. Clin Pharmacol Ther. 2020;107(1):47\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2620_CR16","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.celrep.2019.07.059","volume":"28","author":"AL Burrack","year":"2019","unstructured":"Burrack AL, et al. Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma. Cell Rep. 2019;28(8):2140-2155.e6.","journal-title":"Cell Rep"},{"issue":"4","key":"2620_CR17","doi-asserted-by":"publisher","first-page":"S1142","DOI":"10.1016\/annonc\/annonc325","volume":"31","author":"DJ Renouf","year":"2020","unstructured":"Renouf DJ, et al. The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). Ann Oncol. 2020;31(4):S1142\u2013215. https:\/\/doi.org\/10.1016\/annonc\/annonc325.","journal-title":"Ann Oncol"},{"issue":"3","key":"2620_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12094-013-1079-0","volume":"16","author":"Y Homma","year":"2014","unstructured":"Homma Y, et al. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin Transl Oncol. 2014;16(3):330\u20135.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"2620_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MPA.0b013e3182373a66","volume":"41","author":"T Yamamoto","year":"2012","unstructured":"Yamamoto T, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas. 2012;41(3):409\u201315.","journal-title":"Pancreas"},{"issue":"1","key":"2620_CR20","doi-asserted-by":"publisher","first-page":"7848","DOI":"10.1038\/s41598-017-08479-9","volume":"7","author":"T Shen","year":"2017","unstructured":"Shen T, et al. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Sci Rep. 2017;7(1):7848.","journal-title":"Sci Rep"},{"issue":"8","key":"2620_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.sjbs.2017.11.006","volume":"24","author":"PJ Peng","year":"2017","unstructured":"Peng PJ, Li Y, Sun S. On the significance of Tim-3 expression in pancreatic cancer. Saudi J Biol Sci. 2017;24(8):1754\u20137.","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"2620_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00262-019-02449-y","volume":"69","author":"J Waidhauser","year":"2020","unstructured":"Waidhauser J, et al. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020;69(1):147\u201357.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-021-02620-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-021-02620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T13:34:20Z","timestamp":1632231260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-021-02620-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s12094-021-02620-x","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"13 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Kobold received research support from TCR2 Inc. and Arcus Biosciences outside the submitted work. S. Boeck reports personal fees from Celgene, AstraZeneca and Servier (honoraria for scientific presentations and paid consultant), as well as research support from Celgene outside the submitted work. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and local regulatory requirements. The study protocol was reviewed and approved by the Ethics Committees of Ludwig-Maximilians-University, Munich, Germany (approval number 284-10), and written informed consent was obtained from each patient before any study specific procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate and consent for publication"}}]}}